Active, not recruitingPhase 1NCT04707248
A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
Studying MITF-related melanoma and renal cell carcinoma predisposition syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Daiichi Sankyo
- Principal Investigator
- Global Clinical LeaderDaiichi Sankyo
- Intervention
- DS-6000a(drug)
- Enrollment
- 179 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2026
Study locations (13)
- Arizona Oncology Associates, PC HOPE (A)A HOPE), Tucson, Arizona, United States
- Rocky Mountain Cancer Center, Denver, Colorado, United States
- Florida Cancer Lake Mary, Lake Mary, Florida, United States
- Oklahoma University, Oklahoma City, Oklahoma, United States
- SCRI Oncology Partners, Nashville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
- National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
- National Cancer Center Hospital East, Kashiwa-shi, Tokyo, Japan
- National Hospital Organization Kyusyu Cancer Center, Fukuoka, Japan
- The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Kōtoku, Japan
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
- Shizuoka Cancer Center, Nakatogari, Japan
- Saitama Medical University International Medical Center, Saitama, Japan
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04707248 on ClinicalTrials.govOther trials for MITF-related melanoma and renal cell carcinoma predisposition syndrome
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT06307431A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).Merck Sharp & Dohme LLC
- RECRUITINGPHASE3NCT05078047Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IOUNICANCER
- RECRUITINGNCT05785052Biomarkers of Renal CancerBiorek S.R.L.
- ACTIVE NOT RECRUITINGPHASE1NCT03170960Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsExelixis
- RECRUITINGNCT00001238Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant DisordersNational Cancer Institute (NCI)
See all trials for MITF-related melanoma and renal cell carcinoma predisposition syndrome →